De-Differentiation Confers Multidrug Resistance Via Noncanonical PERK-Nrf2 Signaling
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Malignant carcinomas that recur following therapy are typically de-differentiated and multidrug resistant (MDR). De-differentiated cancer cells acquire MDR by up-regulating reactive oxygen species (ROS)-scavenging enzymes and drug efflux pumps, but how these genes are up-regulated in response to de-differentiation is not known. Here, we examine this question by using global transcriptional profiling to identify ROS-induced genes that are already up-regulated in de-differentiated cells, even in the absence of oxidative damage. Using this approach, we found that the Nrf2 transcription factor, which is the master regulator of cellular responses to oxidative stress, is preactivated in de-differentiated cells. In de-differentiated cells, Nrf2 is not activated by oxidation but rather through a noncanonical mechanism involving its phosphorylation by the ER membrane kinase PERK. In contrast, differentiated cells require oxidative damage to activate Nrf2. Constitutive PERK-Nrf2 signaling protects de-differentiated cells from chemotherapy by reducing ROS levels and increasing drug efflux. These findings are validated in therapy-resistant basal breast cancer cell lines and animal models, where inhibition of the PERK-Nrf2 signaling axis reversed the MDR of de-differentiated cancer cells. Additionally, analysis of patient tumor datasets showed that a PERK pathway signature correlates strongly with chemotherapy resistance, tumor grade, and overall survival. Collectively, these results indicate that de-differentiated cells up-regulate MDR genes via PERK-Nrf2 signaling and suggest that targeting this pathway could sensitize drug-resistant cells to chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“are both resistant to a wide range of chemotherapies [15–19].”
BackgroundProtein translation and folding are coupled by an endoplasmic-reticulum-resident kinase
Harding, H. P., Zhang, Y., & Ron, D. (1999) · Nature · doi:10.1038/16729 · Cited by 3,310 · cited 1×
“In particular, Nrf2 is directly phosphorylated and activated by the ER-membrane kinase PERK, which is canonically activated under conditions of ER stress as part of the unfolded protein response (UPR) [40–42].”
BackgroundAssociation of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“are both resistant to a wide range of chemotherapies [15–19].”
BackgroundHeme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications
Maines, M. D. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.10.3290025 · Cited by 1,707 · cited 1×
“HMOX-1 is a well-characterized enzyme involved in the metabolism of heme, but is also a major target of master antioxidant regulator Nrf2 [29–31].”
BackgroundMolecular mechanisms of N-acetylcysteine actions
Zafarullah, M., Li, W. Q., Sylvester, J., & Ahmad, M. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180300001 · Cited by 1,343 · cited 1×
“Treatment with a ROS-scavenging agent n-acetyl cysteine (NAC) was able to rescue this decreased survival, indicating that PERK pathway activation contributes to chemotherapy resistance in significant part via ROS buffering (Figure 4c,d) [46].”
BackgroundRamos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 1×
“This finding is of particular interest given Nrf2’s known role in promoting chemotherapy survival [34] and its constitutive activation by mutation in a subset of tumors [52–54].”
BackgroundHuman breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., & Weinberg, R. A. (2001) · Genes & Development · doi:10.1101/gad.828901 · Cited by 878 · cited 1×
“differentiated through induction of an EMT—achieved by expressing the Twist transcription factor [24,25].”
Background
Cited by
UPR, autophagy, and mitochondria crosstalk underlies the ER stress response
Senft, D., & Ronai, Z. A. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.01.002 · Cited by 1,121
Proteostasis control by the unfolded protein response
Hetz, C., Chevet, E., & Oakes, S. A. (2015) · Nature Cell Biology · doi:10.1038/ncb3184 · Cited by 748
Endoplasmic Reticulum Stress and the Hallmarks of Cancer
Urra, H., Dufey, E., Avril, T., Chevet, E., & Hetz, C. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.03.007 · Cited by 615
Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.011 · Cited by 598
Self-citationEndoplasmic Reticulum Stress–Activated Cell Reprogramming in Oncogenesis
Chevet, E., Hetz, C., & Samali, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1490 · Cited by 380
Metadata
- Authors
- Del Vecchio, C. A., Feng, Y., Sokol, E. S., Tillman, E. J., Sanduja, S., Reinhardt, F., & Gupta, P. B.
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-09-09
- Volume
- 12
- Issue
- 9
- Pages
- e1001945
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- OpenAlex
- W2003714060
- Cited by
- 116
- References
- 12
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: De-Differentiation Confers Multidrug Resistance Via Noncanonical PERK-Nrf2 Signaling. https://app.cochat.ai/papers/10.1371/journal.pbio.1001945
- The paper
- Del Vecchio, C. A., Feng, Y., Sokol, E. S., Tillman, E. J., Sanduja, S., Reinhardt, F., & Gupta, P. B. (2014). De-Differentiation Confers Multidrug Resistance Via Noncanonical PERK-Nrf2 Signaling. PLoS Biology. https://doi.org/10.1371/journal.pbio.1001945
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.